JP2007513190A5 - - Google Patents

Download PDF

Info

Publication number
JP2007513190A5
JP2007513190A5 JP2006542888A JP2006542888A JP2007513190A5 JP 2007513190 A5 JP2007513190 A5 JP 2007513190A5 JP 2006542888 A JP2006542888 A JP 2006542888A JP 2006542888 A JP2006542888 A JP 2006542888A JP 2007513190 A5 JP2007513190 A5 JP 2007513190A5
Authority
JP
Japan
Prior art keywords
times per
present
per week
factor
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006542888A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007513190A (ja
JP4738346B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/041070 external-priority patent/WO2005055950A2/en
Publication of JP2007513190A publication Critical patent/JP2007513190A/ja
Publication of JP2007513190A5 publication Critical patent/JP2007513190A5/ja
Application granted granted Critical
Publication of JP4738346B2 publication Critical patent/JP4738346B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006542888A 2003-12-03 2004-12-03 ＧｌｙｃｏＰＥＧ化された第ＩＸ因子 Expired - Fee Related JP4738346B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US52708903P 2003-12-03 2003-12-03
US60/527,089 2003-12-03
US53938704P 2004-01-26 2004-01-26
US60/539,387 2004-01-26
US59274404P 2004-07-29 2004-07-29
US60/592,744 2004-07-29
US61451804P 2004-09-29 2004-09-29
US60/614,518 2004-09-29
US62338704P 2004-10-29 2004-10-29
US60/623,387 2004-10-29
PCT/US2004/041070 WO2005055950A2 (en) 2003-12-03 2004-12-03 Glycopegylated factor ix

Publications (3)

Publication Number Publication Date
JP2007513190A JP2007513190A (ja) 2007-05-24
JP2007513190A5 true JP2007513190A5 (https=) 2008-08-28
JP4738346B2 JP4738346B2 (ja) 2011-08-03

Family

ID=34682416

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006542888A Expired - Fee Related JP4738346B2 (ja) 2003-12-03 2004-12-03 ＧｌｙｃｏＰＥＧ化された第ＩＸ因子

Country Status (10)

Country Link
EP (1) EP1694315A4 (https=)
JP (1) JP4738346B2 (https=)
KR (1) KR101209111B1 (https=)
AU (1) AU2004296860B2 (https=)
BR (1) BRPI0417341A (https=)
CA (1) CA2549413A1 (https=)
IL (1) IL175661A0 (https=)
MX (1) MXPA06006023A (https=)
NZ (1) NZ546733A (https=)
WO (1) WO2005055950A2 (https=)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763769B2 (en) 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
NZ542094A (en) 2003-03-14 2008-12-24 Neose Technologies Inc Branched polymer conjugates comprising a peptide and water-soluble polymer chains
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
PL1615945T3 (pl) 2003-04-09 2012-03-30 Ratiopharm Gmbh Sposoby glikopegylacji i białka/peptydy wytwarzane tymi sposobami
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
NZ548123A (en) 2004-01-08 2010-05-28 Novo Nordisk As O-linked glycosylation of peptides
CA2571292C (en) * 2004-06-30 2013-05-21 Nektar Therapeutics Al, Corporation Polymer-factor ix moiety conjugates
AU2014280936B2 (en) * 2004-06-30 2016-12-15 Nektar Therapeutics Polymer-factor ix moiety conjugates
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
WO2006031811A2 (en) 2004-09-10 2006-03-23 Neose Technologies, Inc. Glycopegylated interferon alpha
WO2006050247A2 (en) 2004-10-29 2006-05-11 Neose Technologies, Inc. Remodeling and glycopegylation of fibroblast growth factor (fgf)
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
WO2006121569A2 (en) 2005-04-08 2006-11-16 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
EP2975135A1 (en) * 2005-05-25 2016-01-20 Novo Nordisk A/S Glycopegylated factor IX
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
MX2008002395A (es) * 2005-08-19 2008-03-18 Neose Technologies Inc Factor vii y factor viia glicopegilados.
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
EP2049144B8 (en) * 2006-07-21 2015-02-18 ratiopharm GmbH Glycosylation of peptides via o-linked glycosylation sequences
EP2054521A4 (en) 2006-10-03 2012-12-19 Novo Nordisk As PROCESS FOR CLEANING POLYPEPTIDE CONJUGATES
ES2655734T3 (es) * 2006-10-04 2018-02-21 Novo Nordisk A/S Glicopéptidos y azúcares pegilados unidos a glicerol
PT2101821E (pt) 2006-12-15 2014-10-03 Baxter Int Fator conjugado viia-ácido (poli)siálico com prolongamento do tempo de meia vida in vivo
HRP20130382T1 (hr) 2007-04-03 2013-05-31 Biogenerix Ag Postupci lijeäśenja pomoä†u glikopegiliranog g-csf
JP6050927B2 (ja) * 2007-04-26 2016-12-21 シーエヌジェイ ホールディングス，インコーポレイテッド 高シアル酸含量を有する組換えビタミンｋ依存性タンパク質およびその調製方法
CA2690611C (en) 2007-06-12 2015-12-08 Novo Nordisk A/S Improved process for the production of nucleotide sugars
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
CN102026653B (zh) * 2007-10-15 2014-06-18 北卡罗来纳-查佩尔山大学 半衰期延长的人因子ⅸ变体
NZ603997A (en) * 2007-12-27 2013-02-22 Baxter Int Chemically Modified Factor IX
PL2257311T3 (pl) 2008-02-27 2014-09-30 Novo Nordisk As Koniugaty cząsteczek czynnika VIII
SG189790A1 (en) * 2008-04-16 2013-05-31 Bayer Healthcare Llc Modified factor ix polypeptides and uses thereof
EP3093029A1 (en) 2009-07-27 2016-11-16 Baxalta GmbH Blood coagulation protein conjugates
ES2597954T3 (es) 2009-07-27 2017-01-24 Baxalta GmbH Conjugados de proteína de la coagulación sanguínea
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
JP5909755B2 (ja) 2009-07-27 2016-04-27 リポクセン テクノロジーズ リミテッド 非血液凝固タンパク質の糖ポリシアル酸化
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
JP2013500726A (ja) * 2009-07-31 2013-01-10 バイエル・ヘルスケア・エルエルシー 改変第ｉｘ因子ポリペプチドおよびその使用
US8697844B2 (en) 2009-11-24 2014-04-15 Novo Nordisk A/S Method of purifying pegylated proteins
PL3552619T3 (pl) 2010-07-09 2025-12-01 Bioverativ Therapeutics Inc. Polipeptydy czynnika ix i sposoby ich zastosowania
BR112013015898A2 (pt) 2010-12-22 2018-06-26 Baxter International Inc. derivado de ácido graxo solúvel em água, e, métodos para preparar um derivado de ácido graxo e uma proteína terapêutica conjugada.
TW201519900A (zh) * 2013-04-28 2015-06-01 Bayer Healthcare Llc 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法
AU2020242945B2 (en) 2019-03-19 2025-06-26 CSL Innovation Pty Ltd Factor IX variants and uses thereof in therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59172425A (ja) * 1983-03-18 1984-09-29 Nippon Chemiphar Co Ltd 新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
AU744303B2 (en) * 1997-12-01 2002-02-21 Neose Technologies, Inc. Enzymatic synthesis of gangliosides
ES2411007T3 (es) * 2001-10-10 2013-07-04 Novo Nordisk A/S Remodelación y glicoconjugación de péptidos

Similar Documents

Publication Publication Date Title
JP2007513190A5 (https=)
Liu et al. Polymersome wound dressing spray capable of bacterial inhibition and H2S generation for complete diabetic wound healing
Bąk et al. Challenges and opportunities for celecoxib repurposing
US8003696B2 (en) Composition and method for treating bacterial, viral, fungal diseases, inflammation and pain
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
JP2019515908A5 (https=)
HUP0402230A2 (hu) Többszörös bevonattal ellátott gyógyszer dózisforma
CN108348894A (zh) 用于化合物活化以及臭氧降解的臭氧解
CA3162623A1 (en) Aerosolization systems, methods, and apparatuses
WO2006070325A3 (en) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
RU2007101695A (ru) Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения
Yang et al. Nonlinear and mixed inhibitory effect of matrine on the cytotoxicity of oligomeric amyloid-β protein
US11571455B2 (en) Methods and compositions for treating alcoholic liver disease
WO2022117221A1 (en) Luminol for the prophylaxis and the treatment of sequelae of a sars-cov-2 infection
HRP960070A2 (en) Use of quinoxaline and protease inhibitors in a composition for the treatment of aids and/or hiv infections
CN113365617B (zh) 用于医学疾病治疗的一氧化碳前药
JP2009538935A5 (https=)
CN101346137A (zh) 含有孔布勒塔斯塔坦与抗癌剂的组合物
JP2018123140A (ja) 活性成分（ｉ）含有組成物及びその製造方法
AU2006340367B2 (en) Composition for treating bacterial, viral, fungal diseases, inflammation and pain
JP2008517977A5 (https=)
Raij Mechanisms of vascular injury: the emerging role of the endothelium.
JP2016521760A (ja) がんの処置のための、ｒｏ５５０３７８１、カペシタビン及びオキサリプラチンの組み合わせ
WO2007132280A1 (en) Isatin and its derivatives for use as a medicament
WO2024054558A2 (en) Compositions and methods for amelioration of symptoms associated with clec16a dysfunction or loss